Cargando…

Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells

Endoglin (Eng) is a co-receptor of the transforming growth factor β superfamily playing an important role in endothelial dysfunction. TRC105 (carotuximab) is a monoclonal antibody that blocks Eng and its downstream Smad signaling pathway. Here we have investigated for the first time the effects of T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripska, Katarina, Igreja Sá, Ivone Cristina, Vasinova, Martina, Vicen, Matej, Havelek, Radim, Eissazadeh, Samira, Svobodova, Zuzana, Vitverova, Barbora, Theuer, Charles, Bernabeu, Carmelo, Nachtigal, Petr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490272/ https://www.ncbi.nlm.nih.gov/pubmed/36160139 http://dx.doi.org/10.3389/fmed.2022.845918

Ejemplares similares

Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts
por: Vitverova, Barbora, et al.
Publicado: (2020)

High Soluble Endoglin Levels Affect Aortic Vascular Function during Mice Aging
por: Nejmanová, Iveta, et al.
Publicado: (2021)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
por: Liu, Yingmiao, et al.
Publicado: (2014)

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients
por: Víšek, J., et al.
Publicado: (2021)

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
por: Liu, Yingmiao, et al.
Publicado: (2014)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
por: Ahluwalia, Manmeet S., et al.
Publicado: (2023)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis
por: Cristina Igreja Sá, Ivone, et al.
Publicado: (2023)

MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells
por: Aristorena, Mikel, et al.
Publicado: (2019)

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells
por: Brossa, Alessia, et al.
Publicado: (2018)

High Soluble Endoglin Levels Do Not Induce Endothelial Dysfunction in Mouse Aorta
por: Nemeckova, Ivana, et al.
Publicado: (2015)

An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
por: Mehta, C R, et al.
Publicado: (2019)

In Vivo Tumor Vasculature Targeted PET/NIRF Imaging with TRC105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2014)

Expression of endoglin (CD105) in cervical cancer
por: Zijlmans, H J, et al.
Publicado: (2009)

Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma
por: Di Paolo, Virginia, et al.
Publicado: (2018)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-β
por: Rossi, Elisa, et al.
Publicado: (2019)

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022)

ENDOGLIN Is Dispensable for Vasculogenesis, but Required for Vascular Endothelial Growth Factor-Induced Angiogenesis
por: Liu, Zhen, et al.
Publicado: (2014)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Study of expression of endoglin (CD105) in oral squamous cell carcinoma
por: Mahapatra, Niva, et al.
Publicado: (2021)

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
por: Vaklavas, Christos, et al.
Publicado: (2023)

Endoglin – a marker of vascular endothelial cell proliferation in cancer
por: Kopczyńska, Ewa, et al.
Publicado: (2012)

Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
por: Kasprzak, Aldona, et al.
Publicado: (2018)

Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
por: Nogués, Ana, et al.
Publicado: (2020)

Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling
por: Kumar, S, et al.
Publicado: (2014)

Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies
por: Nolan-Stevaux, Olivier, et al.
Publicado: (2012)

Endoglin Is an Endothelial Housekeeper against Inflammation: Insight in ECFC-Related Permeability through LIMK/Cofilin Pathway
por: Rossi, Elisa, et al.
Publicado: (2021)

Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
por: Anderberg, Charlotte, et al.
Publicado: (2013)

TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007)

Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma
por: Yu, Decai, et al.
Publicado: (2007)

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
por: Bock, Annika J., et al.
Publicado: (2011)

ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours
por: Gromova, Petra, et al.
Publicado: (2012)

Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2020)

Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2021)

Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review
por: Sier, Vincent Q., et al.
Publicado: (2021)

Horoscopic role of CD105 (Endoglin) in progression of oral lichen planus: An immunohistochemical study
por: Parvathala, Poornima, et al.
Publicado: (2021)

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
por: Rossi, Edoardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2205ajvqa9ddgi0c879q7nu4qf